|
May 3
|
Resolutions at BioInvent's Annual General Meeting 2024
|
|
Apr 2
|
BioInvent Announces a New Clinical Trial Collaboration and Supply Agreement with MSD to Evaluate BI-1910, the Company’s Second Anti-TNFR2 Antibody in Combination with KEYTRUDA(R) (Pembrolizumab)
|
|
Mar 27
|
Notice to Annual General Meeting in BioInvent International AB
|
|
Mar 5
|
CASI Pharmaceuticals Report Positive Interim Phase 1 Data For BI-1206 In The Treatment Of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma In China
|
|
Jan 12
|
BioInvent Regains Rights to Immuno-Oncology Targets from Exelixis
|